Bristol Myers Squibb have announced that construction is underway for a new cell therapy manufacturing facility in Devens, Massachusetts, a part of its investment to support clinical and commercial manufacturing of transformative cell therapies for patients with aggressive hematological cancers.
The Devens site is the latest investment from Bristol Myers Squibb as the company seeks to expand its global manufacturing network. The 244,000 square foot facility will add new technologies and manufacturing teams to the company’s established cell therapy manufacturing network. The Devens site will be equipped to enable quick ramp up of capacity for clinical and commercial cell therapy products.
"Bristol Myers Squibb is at the forefront of manufacturing innovations, and we are proud that our new cell therapy facility in the Boston area will include many next generation technologies and the latest integrated digital systems," said Ann Lee, Ph.D., head, Cell Therapy Development & Operations, Bristol Myers Squibb. "Bristol Myers Squibb has designed a reliable manufacturing and global supply chain network comprised of internal manufacturing facilities, which include Bothell, Wash., Summit, N.J., and Warren, N.J. in the U.S., as well as external manufacturing facilities in the U.S., Europe and Japan. Expanding our global footprint is critical to supplying these transformational products to patients around the world."
The new facility will be located on BMS’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines, including an immuno-oncology medicine. The new cell therapy facility allows accelerated career development for current and prospective employees across biologics and cell therapies on a single campus, with employees having access to all existing campus amenities. The company plans to hire several hundred employees over the next few years to support the new operations.
BMS also operates two R&D facilities in Cambridge, MA and will be bringing those two sites together into a new building at Cambridge Crossing in 2023.
Read the BMS statement